Taysha Gene Therapies (TSHA) Amortization of Deferred Charges (2022 - 2026)

Taysha Gene Therapies (TSHA) has 5 years of Amortization of Deferred Charges data on file, last reported at $285000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges fell 15.93% year-over-year to $285000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 6.01% YoY), and the FY2025 full-year result was $1.4 million, up 11.67% from the prior year.
• Amortization of Deferred Charges declined to $285000.0 in Q1 2026, from $400000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $400000.0 in Q4 2025 to a low of $274000.0 in Q4 2023.
• A 5-year average of $315176.5 and a median of $305000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges declined 20.78% in 2023 and surged 32.89% in 2025, its largest moves.
• Tracing TSHA's Amortization of Deferred Charges over 5 years: stood at $284000.0 in 2022, then decreased by 3.52% to $274000.0 in 2023, then grew by 9.85% to $301000.0 in 2024, then surged by 32.89% to $400000.0 in 2025, then declined by 28.75% to $285000.0 in 2026.
• Business Quant data shows TSHA's Amortization of Deferred Charges at $285000.0 in Q1 2026, $400000.0 in Q4 2025, and $312000.0 in Q3 2025.